Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Armata Pharmaceuticals (ARMP) EBT (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed EBT for 6 consecutive years, with -$1.1 million as the latest value for Q4 2018.

  • Quarterly EBT fell 122.68% to -$1.1 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was -$10.1 million through Dec 2018, down 43.22% year-over-year, with the annual reading at -$53.2 million for FY2025, 0.09% changed from the prior year.
  • EBT hit -$1.1 million in Q4 2018 for Armata Pharmaceuticals, up from -$2.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $4.9 million in Q4 2017 to a low of -$11.3 million in Q1 2014.
  • Historically, EBT has averaged -$3.2 million across 5 years, with a median of -$3.0 million in 2015.
  • Biggest five-year swings in EBT: tumbled 691.25% in 2014 and later surged 231.26% in 2017.
  • Year by year, EBT stood at -$2.6 million in 2014, then dropped by 13.21% to -$2.9 million in 2015, then decreased by 25.78% to -$3.7 million in 2016, then soared by 231.26% to $4.9 million in 2017, then plummeted by 122.68% to -$1.1 million in 2018.
  • Business Quant data shows EBT for ARMP at -$1.1 million in Q4 2018, -$2.8 million in Q3 2018, and -$3.2 million in Q2 2018.